

Summary of Consolidated Financial Results for the nine months Ended December 31, 2010

February 2, 2011

Listed company name : Sysmex Corporation
 Code : 6869
 Listed stock exchanges : Tokyo Stock Exchange
 Osaka Securities Exchange
 URL : <http://www.sysmex.co.jp>
 Company representative : Hisashi Ietsugu, President and CEO
 Contact : Yukitoshi Kamao, Executive Vice President,
 Corporate Business Administration
 Phone : 078(265)-0500
 Scheduled date for filing of quarterly report : February 10, 2011
 Scheduled date for dividend payment : —
 Preparation of supplementary material for quarterly earnings : Yes
 Holding of quarterly earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the nine months ended December 31, 2010

(1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

| | Net Sales | | Operating income | | Ordinary income | | Net income | |
|---------------------------------|-----------|------|------------------|-------|-----------------|-------|------------|-------|
| Nine months ended Dec. 31, 2010 | 89,712 | 7.9% | 13,449 | 20.8% | 12,894 | 16.4% | 8,031 | 19.1% |
| Nine months ended Dec. 31, 2009 | 83,162 | 3.1% | 11,132 | 10.3% | 11,081 | 40.5% | 6,741 | 46.2% |

| | Net income per share (Yen) | Diluted net income per share (Yen) |
|---------------------------------|----------------------------|------------------------------------|
| Nine months ended Dec. 31, 2010 | 156.51 | 156.19 |
| Nine months ended Dec. 31, 2009 | 131.75 | 131.57 |

(2) Financial condition

| | Total assets | Net assets | Equity Ratio | Net assets per share (Yen) |
|---------------------|--------------|------------|--------------|----------------------------|
| As of Dec. 31, 2010 | 121,437 | 89,085 | 72.7% | 1,720.84 |
| As of Mar. 31, 2010 | 120,702 | 87,136 | 71.5% | 1,684.90 |

Note:

Equity capital: 88,345 million yen as of December 31, 2010; 86,357 million yen as of March 31, 2010

2. Dividends (The year ended March 31, 2010 and the year ending March 31, 2011)

| | Dividend per share | | | | |
|--------------------------------------|---------------------|----------------------|---------------------|----------------|--------------|
| | First quarter (Yen) | Second quarter (Yen) | Third quarter (Yen) | Year-end (Yen) | Annual (Yen) |
| Year ended Mar. 31, 2010 | — | 25.00 | — | 31.00 | 56.00 |
| Year ending Mar. 31, 2011 | — | 28.00 | — | | |
| Year ending Mar. 31, 2011 (Forecast) | | | | 28.00 | 56.00 |

Note:

Revision of dividends forecast for this period: No

3. Business forecast for the year ending March 31, 2011

(% changes as compared with the corresponding period of the previous fiscal year)

| | Net Sales | | Operating income | | Ordinary income | | Net income | | Net income per share (Yen) |
|---------------------------|-----------|------|------------------|-------|-----------------|------|------------|-------|----------------------------|
| Year ending Mar. 31, 2011 | 123,000 | 5.9% | 17,500 | 11.4% | 16,800 | 6.5% | 10,800 | 10.6% | 210.43 |

Note:

Revision of business forecast for this period: No

4. Other information

- (1) Changes in significant subsidiaries: No
- (2) Application of simplified accounting method and special accounting policy for quarterly financial reporting: Yes
- (3) Changes in accounting procedures
 - 1) Changes based on revisions of accounting standard: Yes
 - 2) Other changes: Yes
- (4) Number of shares outstanding (Ordinary shares)
 - 1) Number of shares outstanding at the end of each fiscal period (including treasury stock):
51,446,108 shares as of Dec. 31, 2010; 51,353,708 shares as of Mar. 31, 2010
 - 2) Number of treasury stock at the end of each fiscal period:
107,568 shares as of Dec. 31, 2010; 99,726 shares as of Mar. 31, 2010
 - 3) Average number of outstanding stock for each period (cumulative):
51,317,248 shares nine months ended Dec. 31, 2010; 51,172,229 shares nine months ended Dec. 31, 2009

*It is under the review procedure based on the Financial Instruments and Exchange Act at the time of disclosure of this report.

*The above estimates are based on information available to the company on the date of the report's announcement. Due to unforeseen circumstances, however, actual results may differ from such estimates.

[Financial Performance]

1. Performance analysis

During the first nine months of the fiscal year ending March 31, 2011 (April 1 to December 31, 2010), the Japanese economy was characterized by an increase in exports, supported by economic expansion in emerging markets, centered on China. And the economy was in a recovery phase, triggered by government economic stimulus measures. However, the period was marked by a growing sense of uncertainty, prompted by such factors as rapid appreciation of the yen against other currencies, the ongoing scarcity of job opportunities and progressive deflation. These factors, coupled with the European debt crisis and decelerating economic activity in the United States, make it difficult to remain positive about the global economic outlook.

On the healthcare front, earnings and profits at medical institutions in Japan are beginning to improve, prompted by the restructuring of public hospitals and revisions in medical remuneration. In advanced countries in Europe and North America, efforts are underway to reduce healthcare costs and reform medical systems. In the United States, implementation has begun on a medical reform bill that aims to reduce the number of people without medical insurance. In China, medical system reform that is underway aims to build infrastructures that provide uniform medical services in cities and farming villages throughout the country.

Amid these conditions, in a bid to further expand its share of the urinalysis market the Sysmex Group commenced sales of the world's first fully automated integrated urine analyzer, jointly developed with ARKRAY, Inc. The Sysmex Group also extended its product lineup for China and other parts of Asia by signing agreements with JEOL Ltd. and Furuno Electric Co., Ltd., involving automated clinical chemistry analyzers in these regions. In addition, the Group commenced work on expanding a reagent production facility in Jinan, China, to meet rapid demand growth in the country.

Net Sales by Destination

| First Nine Months Ended December 31, 2010 | 2009 | | 2010 | | Percentage of Previous Year's Figure (%) |
|--|--------------------------------|----------------------------|--------------------------------|----------------------------|---|
| | Amount (Millions of Yen) | Percentage of Total (%) | Amount (Millions of Yen) | Percentage of Total (%) | |
| Japan | 25,392 | 30.5 | 26,666 | 29.7 | 105.0 |
| Americas | 16,694 | 20.1 | 19,231 | 21.4 | 115.2 |
| Europe | 26,961 | 32.4 | 25,767 | 28.7 | 95.6 |
| China | 8,719 | 10.5 | 11,363 | 12.7 | 130.3 |
| Asia Pacific | 5,395 | 6.5 | 6,683 | 7.5 | 123.9 |
| Overseas subtotal | 57,769 | 69.5 | 63,046 | 70.3 | 109.1 |
| Total | 83,162 | 100.0 | 89,712 | 100.0 | 107.9 |

In Japan, our ongoing efforts to promote solutions led to solid sales in hematology and other fields, as well as the acquisition of a major order. This offset a decrease in sales of our influenza detection kit, POCTEM, following the spread of the new influenza virus in the preceding term. As a result, we posted third-quarter net sales of ¥26,666 million, up 5.0%, compared with the third quarter of the previous fiscal year.

In overseas markets, we made steady progress in the strengthening of sales and support structures and the provision of solutions. As a result, sales moved steadily upward on a local currency basis due to increased sales of instruments and diagnostic reagents. Consequently, despite major yen appreciation the Group's overseas sales were ¥63,046 million, up 9.1% year on year. The overseas sales ratio was 70.3%, up 0.8 percentage points from the same period of the previous fiscal year.

As a result, during the third quarter the Group recorded consolidated net sales of ¥89,712 million, up 7.9%. Operating income grew 20.8%, to ¥13,449 million; ordinary income rose 16.4%, to ¥12,894 million; and net income expanded 19.1%, to ¥8,031 million.

Performance by segment

(1) Japan

Performance remained robust in the hematology field, our main business domain, and our perseverance in presenting solutions to customers paid off in the form of large orders. These factors contributed to a 9.5% rise in net sales compared with the corresponding period of the preceding fiscal year, to ¥29,188 million, despite a decline in sales of influenza testing kits, POCTEM, which contributed to performance in the previous year.

Despite the negative effects on income of yen appreciation, we posted operating income of ¥5,316 million, up 138.5% from the third quarter of the previous year. This rise was the result of higher gross profit, stemming from an improved cost ratio, progress in reducing costs and an increase in export sales to Group companies, including the impact of a revision in intragroup transaction prices. Also contributing to the increase was a change in the method of recording the royalty income, including it in net sales rather than in non-operating income.

(2) Americas

In the United States, sales grew as a result of our focus on developing direct sales and support networks, as well as our success in promoting solutions that meet customer needs, which earned us orders from integrated health networks (IHNs), the U.S. Veterans Integrated Service Network (VISN) and prominent commercial labs. As a result, despite the negative effects of yen appreciation, sales in the Americas grew 10.7%, to ¥18,364 million.

Compensating for the higher cost of sales resulting from a revision in intragroup transaction prices and an increase in selling, general and administrative expenses, the rise in sales prompted a 17.2% increase in operating income, to ¥2,198 million.

(3) Europe

In addition to expanding our direct sales and support structure, sales began to recover in the Italy and Spain, despite the lingering impact of financial crises. Although sales were robust on a local-currency basis, centered on the hematology field, net sales in this region dropped 4.5% year on year, to ¥25,704 million, affected by substantial appreciation of the yen against the euro.

Although up on a local currency basis, significant yen appreciation caused operating income to fall 8.0% in yen terms, to ¥3,564 million.

(4) China

In China, sales surged 30.3%, to ¥11,363 million. Behind these solid results were substantially higher sales in the hematology, hemostasis and urinalysis fields.

Owing to higher sales, which compensated for the higher cost of sales resulting from a revision in intragroup transaction prices, operating income rose 0.6%, to ¥2,176 million.

(5) Asia Pacific

Favorable sales growth continued in India and Indonesia, and a major new order bolstered sales of system products in Malaysia. Consequently, sales increased substantially, centered on the hematology field. Sales in the region amounted to ¥5,092 million, up 19.1%.

Owing to the higher cost of sales resulting from a revision in intragroup transaction prices and an increase in selling, general and administrative expenses, operating income fell 19.4%, to ¥602 million.

2. Financial conditions analysis

(1) Assets, liabilities and net assets

As of December 31, 2010, total assets amounted to ¥121,437 million, up ¥734 million from March 31, 2010. Major reasons for this rise included an ¥684 million increase in cash and deposits, ¥652 million higher work in process, a ¥252 million rise in raw materials and supplies, and among other current assets, lease investment assets increased ¥250 million. Property, plant and equipment fell ¥842 million, and investments and other assets declined ¥470 million.

At the same time, total liabilities fell ¥1,214 million from the end of the preceding fiscal year, to ¥32,351 million. This was due mainly to a ¥1,067 million decline in the provision for bonuses.

Total net assets grew ¥1,949 million, to ¥89,085 million, due mainly to an ¥5,005 million increase in retained earnings, while foreign currency translation adjustments dropped ¥3,244 million. The equity ratio as of December 31, 2010, was 72.7%, up 1.2 percentage points from March 31, 2010.

(2) Cash flows

As of December 31, 2010, cash and cash equivalents amounted to ¥14,491 million, up ¥679 million from March 31, 2010.

Cash flows from various activities are described in more detail below.

(Operating cash flow)

Net cash provided by operating activities was ¥10,999 million, down ¥2,561 million from a year earlier. Income before income taxes provided ¥12,640 million, ¥2,013 million more than in the first three quarters of the preceding fiscal year, but the increase in trade notes and receivable used ¥897 million, compared with ¥4,203 million provided in the previous term. An increase in trade notes and accounts payable provided ¥701 million, compared with ¥2,033 million used in the previous term, and income taxes paid used ¥4,750 million, ¥1,920 million more than in the preceding term.

(Investing cash flow)

Net cash used in investing activities was ¥6,154 million, ¥1,977 million more than in the first three quarters of the preceding fiscal year. The main use of cash was the purchase of property, plant and equipment, which used ¥3,981 million, a ¥1,194 million year-on-year increase.

(Financing cash flow)

Net cash used in financing activities came to ¥3,167 million, down ¥2,255 million. Despite the cash provided by a ¥443 million net increase in short-term loans payable, compared with a ¥1,726 million decrease in the corresponding period of the previous fiscal year, cash dividends paid used ¥3,026 million, ¥417 million more than in the first nine months of the preceding term.

3. Consolidated financial forecast

Third-quarter net sales and profit were higher than in the third quarter of the previous term, and fourth-quarter performance is progressing in line with our expectations. Consequently, we maintain unchanged our consolidated financial forecast for the full year, as announced on November 4, 2010.

The forecasts above are based on information available as of the date of this release. Actual results may differ materially from these forecasts due to unforeseen factors and future events.

Consolidated Balance Sheets

(Unit: Millions of Yen)

| Items | As of December. 31, 2010 | As of Mar. 31, 2010 |
|--|-----------------------------|---------------------|
| | Amount | Amount |
| (Assets) | | |
| I Current assets | | |
| Cash and deposits | 14,520 | 13,835 |
| Notes and accounts receivable-trade | 29,638 | 30,507 |
| Short-term investment securities | 166 | 134 |
| Merchandise and finished goods | 13,784 | 13,988 |
| Work in process | 1,916 | 1,264 |
| Raw materials and supplies | 3,776 | 3,524 |
| Others | 9,314 | 7,999 |
| Allowance for doubtful accounts | (360) | (384) |
| Total current assets | 72,756 | 70,870 |
| II Noncurrent assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 15,346 | 15,827 |
| Others | 19,824 | 20,185 |
| Total Property, plant and equipment | 35,170 | 36,013 |
| Intangible assets | | |
| Goodwill | 1,955 | 1,741 |
| Others | 4,425 | 4,476 |
| Total Intangible assets | 6,380 | 6,218 |
| Total Investments and other assets | 7,129 | 7,599 |
| Total Noncurrent assets | 48,680 | 49,832 |
| Total assets | 121,437 | 120,702 |
| (Liabilities) | | |
| I Current liabilities | | |
| Notes and accounts payable-trade | 10,758 | 10,233 |
| Short-term loans payable | 438 | 16 |
| Income taxes payable | 2,356 | 2,447 |
| Provision for bonuses | 1,869 | 2,936 |
| Provision for directors' bonuses | 169 | 190 |
| Provision for product warranties | 124 | 149 |
| Others | 12,230 | 13,613 |
| Total current liabilities | 27,947 | 29,587 |
| II Noncurrent liabilities | | |
| Long-term loans payable | 9 | 3 |
| Provision for retirement benefits | 862 | 639 |
| Provision for directors' retirement benefits | 160 | 160 |
| Others | 3,371 | 3,175 |
| Total Noncurrent liabilities | 4,404 | 3,978 |
| Total liabilities | 32,351 | 33,565 |
| (Net assets) | | |
| I Shareholders' equity | | |
| Capital stock | 8,997 | 8,824 |
| Capital surplus | 13,936 | 13,763 |
| Retained earnings | 71,281 | 66,276 |
| Treasury stock | (247) | (204) |
| Total shareholders' equity | 93,968 | 88,660 |
| II Valuation and translation adjustments | | |
| Valuation difference on available-for-sale securities | 163 | 270 |
| Deferred gains or losses on derivatives under hedge accounting | 17 | (13) |
| Foreign currency translation adjustment | (5,804) | (2,560) |
| Total valuation and translation adjustments | (5,622) | (2,303) |
| III Subscription rights to shares | 615 | 666 |
| IV Minority interests | 124 | 112 |
| Total net assets | 89,085 | 87,136 |
| Total liabilities and net assets | 121,437 | 120,702 |

(Note) fractions of one million yen are rounded off

Consolidated Statements of Income

(Unit: Millions of Yen)

| Items | Nine months ended December. 31, 2009 | Nine months ended December. 31, 2010 |
|--|---|---|
| | Amount | Amount |
| I Net sales | 83,162 | 89,712 |
| II Cost of sales | 29,514 | 31,975 |
| Gross profit | 53,648 | 57,737 |
| III Selling, general and administrative expenses | 42,515 | 44,287 |
| Operating income | 11,132 | 13,449 |
| IV Non-operating income | | |
| Interest income | 80 | 89 |
| Dividends income | 46 | 48 |
| Income from investment real estate | 288 | 295 |
| Income from business collaboration agreement | - | 214 |
| Others | 229 | 254 |
| Total non-operating income | 645 | 902 |
| V Non-operating expenses | | |
| Interest expenses | 186 | 78 |
| Equity in losses of affiliates | 45 | 45 |
| Maintenance cost of investment real estate | 121 | 112 |
| Foreign exchange losses | 266 | 1,033 |
| Others | 75 | 187 |
| Total non-operating expenses | 696 | 1,457 |
| Ordinary income | 11,081 | 12,894 |
| VI Extraordinary profits | | |
| Gain on sales of noncurrent assets | 48 | 4 |
| Reversal of allowance for doubtful accounts | 9 | 12 |
| Others | 4 | 3 |
| Total extraordinary profits | 61 | 20 |
| VII Extraordinary loss | | |
| Loss on valuation of investment securities | 436 | 38 |
| Loss on sales and retirement of noncurrent assets | 77 | 47 |
| Loss on adjustment for changes of accounting standard for asset retirement obligations | - | 187 |
| Others | 0 | 0 |
| Total extraordinary loss | 514 | 273 |
| Income before income taxes and minority interest | 10,627 | 12,640 |
| Income taxes-current | 3,860 | 4,643 |
| Income taxes-deferred | 12 | (48) |
| Total income taxes | 3,873 | 4,594 |
| Income before minority interests | - | 8,046 |
| Minority interest | 12 | 15 |
| Net income | 6,741 | 8,031 |

(Note) fractions of one million yen are rounded off

Consolidated Statements of Cash Flows

(Unit: Millions of Yen)

| Items | Nine months ended December. 31, 2009 | Nine months ended December. 31, 2010 |
|--|---|---|
| I Net cash provided by (used in) operating activities | | |
| Income before income taxes | 10,627 | 12,640 |
| Depreciation and amortization | 5,149 | 5,076 |
| Loss on adjustment for changes of accounting standard for asset retirement obligations | - | 187 |
| Decrease (increase) in notes and accounts receivable-trade | 4,203 | (897) |
| Decrease (increase) in inventories | (1,620) | (1,737) |
| Increase (decrease) in notes and accounts payable-trade | (2,033) | 701 |
| Others | 124 | (262) |
| Subtotal | 16,450 | 15,709 |
| Interest and dividends received | 110 | 111 |
| Interest expenses paid | (171) | (70) |
| Income taxes paid | (2,830) | (4,750) |
| Net cash provided by (used in) operating activities | 13,560 | 10,999 |
| II Net cash provided by (used in) investment activities | | |
| Purchase of property, plant and equipment | (2,786) | (3,981) |
| Purchase of intangible assets | (1,622) | (1,141) |
| Others | 231 | (1,032) |
| Net cash provided by (used in) investment activities | (4,177) | (6,154) |
| III Net cash provided by (used in) financing activities | | |
| Net increase (decrease) in short-term loans payable | (1,726) | 443 |
| Repayment of long-term loans payable | (49) | (7) |
| Cash dividends paid | (2,609) | (3,026) |
| Others | (1,037) | (577) |
| Net cash provided by (used in) financing activities | (5,422) | (3,167) |
| IV Effect of exchange rate change on cash and cash equivalents | (175) | (997) |
| V Net increase (decrease) in cash and cash equivalents | 3,785 | 679 |
| VI Cash and cash equivalents at beginning of term | 9,410 | 13,812 |
| VII Cash and cash equivalents at end of term | 13,195 | 14,491 |

(Note) fractions of one million yen are rounded off

Segment Information

1. Information about operations by geographic area

Nine months ended December 31, 2009

(Unit: Millions of Yen)

| | Japan | Americas | Europe | China | Asia Pacific | Total | Eliminations/ Corporate | Consolidated |
|--------------------------------|--------|----------|--------|-------|--------------|---------|----------------------------|--------------|
| Sales and Operating income | | | | | | | | |
| Sales | | | | | | | | |
| Net Sales to outside customers | 26,650 | 16,590 | 26,927 | 8,719 | 4,274 | 83,162 | - | 83,162 |
| Inter-area transfer | 21,428 | 7 | 373 | 3 | 120 | 21,933 | (21,933) | - |
| Total net sales | 48,079 | 16,597 | 27,301 | 8,722 | 4,395 | 105,095 | (21,933) | 83,162 |
| Operating expenses | 45,850 | 14,722 | 23,427 | 6,559 | 3,648 | 94,206 | (22,176) | 72,030 |
| Operating income | 2,228 | 1,875 | 3,873 | 2,163 | 747 | 10,888 | 243 | 11,132 |

2. Net Sales to Foreign Customers

Nine months ended December 31, 2009

(Unit: Millions of Yen)

| | Americas | Europe | China | Asia Pacific | Total |
|--|----------|--------|-------|--------------|--------|
| Net Sales to Foreign Customers | 16,694 | 26,961 | 8,719 | 5,395 | 57,769 |
| Consolidated Sales | - | - | - | - | 83,162 |
| The rate of net sales to foreign customers to consolidated sales | 20.1% | 32.4% | 10.5% | 6.5% | 69.5% |

(Additional information)

From the three months ended June 30, 2010, the Group applies the "Revised Accounting Standard for Disclosures about Segments of an Enterprise and Related information"(ASBJ Statement No.17 of March 27, 2009) and "Guidance on the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information"(ASBJ Statement No.20 of March 21, 2009) .

Information on sales and income by geographic segment reported

Nine months ended December 31, 2010

(Unit: Millions of Yen)

| | Japan | Americas | Europe | China | Asia Pacific | Total | Adjustment | Consolidated |
|--------------------------------|--------|----------|--------|--------|--------------|---------|------------|--------------|
| Sales and Operating income | | | | | | | | |
| Sales | | | | | | | | |
| Net Sales to outside customers | 29,188 | 18,364 | 25,704 | 11,363 | 5,092 | 89,712 | - | 89,712 |
| Inter-area transfer | 25,787 | 1 | 196 | 4 | 134 | 26,124 | (26,124) | - |
| Total net sales | 54,975 | 18,366 | 25,900 | 11,368 | 5,226 | 115,836 | (26,124) | 89,712 |
| Operating income | 5,316 | 2,198 | 3,564 | 2,176 | 602 | 13,858 | (408) | 13,449 |